Epkinly Dosage & Drug Information

Concise Prescribing Info

Contents

Epcoritamab

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Indications/Uses

Relapsed or refractory diffuse large B-cell lymphoma in adult patients after ≥2 lines of systemic therapy.

Dosage/Direction for Use

SC Cycle 1: 0.16 mg (step-up dose 1) wkly on day 1, 0.8 mg (step-up dose 2) wkly on day 8, 48 mg (1st full dose) wkly on day 15, 48 mg wkly on day 22. Cycles 2-3: 48 mg wkly on days 1, 8, 15 & 22. Cycles 4-9: 48 mg every 2 wk (days 1 & 15). Cycles ≥10: 48 mg every 4 wk (day 1).

Contraindications

Hypersensitivity.

MIMS Class

Targeted Cancer Therapy

ATC Classification

L01FX27 - epcoritamab ; Belongs to the class of other monoclonal antibodies and antibody drug conjugates. Used in the treatment of cancer.

Regulatory Classification

POM

Presentation/Packing

Form

Epkinly conc for soln for inj 4 mg/0.8 mL

Packing/Price

1's

Form

Epkinly soln for inj 48 mg/0.8 mL

Packing/Price

1's

Epkinly

Manufacturer:

Vetter Pharma